
Eli Lilly (LLY) Stock Forecast & Price Target
Eli Lilly (LLY) Analyst Ratings
Bulls say
Eli Lilly reported a strong second quarter of 2025, surpassing expectations on both revenue and earnings while increasing its full-year guidance, indicating robust operational performance. Notably, sales for Mounjaro grew significantly, with a 60% increase quarter-over-quarter driven by new market entries in countries such as Brazil, Mexico, and India, suggesting strong demand for its cardiometabolic product line. Additionally, the introduction of orforglipron as an oral option in the GLP-1 market positions Eli Lilly favorably, enhancing its product offerings and market penetration in a growing therapeutic area.
Bears say
Eli Lilly faces significant downside risks impacting its financial outlook, particularly due to potential pricing and rebate pressures that could affect its market share. The trajectory of tirzepatide prescriptions has been worse than expected, and there are concerns regarding the drug's failure to demonstrate cardiac outcome benefits in specific patient populations, alongside a disappointing performance from Zepbound. Additionally, the competitive landscape is intensifying with orforglipron, which poses a global threat to Lilly's product offerings, further necessitating a reevaluation of peak sales forecasts amid heightened uncertainty.
This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.
Eli Lilly (LLY) Analyst Forecast & Price Prediction
Start investing in Eli Lilly (LLY)
Order type
Buy in
Order amount
Est. shares
0 shares